Windtree Therapeutics, Inc. Change in inventories

Change in inventories of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Change in inventories growth rates and interactive chart.


Highlights and Quick Summary

  • Change in inventories for the quarter ending December 30, 2015 was $0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Change in inventories decreased by -100.0%
  • Annual Change in inventories for 2015 was $201 Thousand (a -111.24% decrease from previous year)
  • Annual Change in inventories for 2014 was $-1.79 Million (a 314.85% increase from previous year)
  • Annual Change in inventories for 2013 was $-431 Thousand (a 121.03% increase from previous year)
  • Twelve month Change in inventories ending December 30, 2015 was $201 Thousand (a -72.54% decrease compared to previous quarter)
  • Twelve month trailing Change in inventories decreased by -139.88% year-over-year
Trailing Change in inventories for the last four month:
30 Dec '15 29 Sep '15 29 Jun '15 30 Mar '15
$201 Thousand $732 Thousand $609 Thousand $-504 Thousand
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Change in inventories of Windtree Therapeutics, Inc.

Most recent Change in inventoriesof WINT including historical data for past 10 years.

Interactive Chart of Change in inventories of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Change in inventories for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2015 $0.0 $0.0 $0.0 $0.2 $0.2
2014 $0.53 $-0.12 $-1.11 $-1.08 $-1.79
2013 $-0.51 $-0.08 $-0.04 $0.2 $-0.43
2012 $-0.07 $-0.02 $-0.11 $-0.2

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.